Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi NajafZadeh

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 22, 2015
Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation StudyJoshua J Gagne, Mehdi Najafzadeh, Niteesh K Choudhry, et al.
Canadian Journal of Diabetes|July 18, 2019
Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice ExperimentJennifer R Donnan, Karissa Johnston, Eugene Chibrikov, et al.
BMC Health Services Research|November 2, 2013
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)Mehdi Najafzadeh, Karissa M Johnston, Stuart J Peacock, et al.
Annals of Internal Medicine|March 17, 2015
Cost-effectiveness of novel regimens for the treatment of hepatitis C virusMehdi Najafzadeh, Karin Andersson, William H Shrank, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 22, 2015
Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care DataJoshua J Gagne, Katsiaryna Bykov, Mehdi Najafzadeh, et al.
Journal of the American Geriatrics Society|June 24, 2023
Common non-cardiovascular multimorbidity groupings and clinical outcomes in older adults with major cardiovascular diseaseStephanie Denise M Sison, Kueiyu Joshua Lin, Mehdi Najafzadeh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndromeLarry D Lynd, Mehdi Najafzadeh, Lindsey Colley, et al.
JAMA Network Open|November 9, 2023
Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral AnticoagulantsKueiyu Joshua Lin, Daniel E Singer, Darae Ko, et al.
Menopause (New York, N.Y.)|March 6, 2020
The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groupsMacarius M Donneyong, Teng-Jen Chang, Joshua A Roth, et al.
Endocrinology, Diabetes & Metabolism|January 11, 2020
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical careElisabetta Patorno, Mehdi Najafzadeh, Ajinkya Pawar, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 22, 2015
Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation StudyJoshua J Gagne, Mehdi Najafzadeh, Niteesh K Choudhry, et al.
Canadian Journal of Diabetes|July 18, 2019
Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice ExperimentJennifer R Donnan, Karissa Johnston, Eugene Chibrikov, et al.
BMC Health Services Research|November 2, 2013
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)Mehdi Najafzadeh, Karissa M Johnston, Stuart J Peacock, et al.
Annals of Internal Medicine|March 17, 2015
Cost-effectiveness of novel regimens for the treatment of hepatitis C virusMehdi Najafzadeh, Karin Andersson, William H Shrank, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 22, 2015
Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care DataJoshua J Gagne, Katsiaryna Bykov, Mehdi Najafzadeh, et al.
Journal of the American Geriatrics Society|June 24, 2023
Common non-cardiovascular multimorbidity groupings and clinical outcomes in older adults with major cardiovascular diseaseStephanie Denise M Sison, Kueiyu Joshua Lin, Mehdi Najafzadeh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndromeLarry D Lynd, Mehdi Najafzadeh, Lindsey Colley, et al.
JAMA Network Open|November 9, 2023
Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral AnticoagulantsKueiyu Joshua Lin, Daniel E Singer, Darae Ko, et al.
Menopause (New York, N.Y.)|March 6, 2020
The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groupsMacarius M Donneyong, Teng-Jen Chang, Joshua A Roth, et al.
Endocrinology, Diabetes & Metabolism|January 11, 2020
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical careElisabetta Patorno, Mehdi Najafzadeh, Ajinkya Pawar, et al.
Pageof 6